Halozyme Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Halozyme Therapeutics Stock Summary

Halozyme Therapeutics competes with Agios Pharm, Insmed, Ultragenyx, Biomarin Pharmaceutical, and Alnylam Pharmaceuticals. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. Halozyme Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people.

Halozyme Therapeutics Key Financial Ratios

Halozyme Therapeutics Key Balance Sheet Accounts

Halozyme Therapeutics Key Income Statement Accounts

Halozyme Therapeutics Key Cash Accounts

Halozyme Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Halozyme Therapeutics's current stock value. Our valuation model uses many indicators to compare Halozyme Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Halozyme Therapeutics competition to find correlations between indicators driving Halozyme Therapeutics's intrinsic value. More Info.Halozyme Therapeutics is one of the top stocks in return on equity category among its peers. It is rated # 2 in return on asset category among its peers reporting about  0.13  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Halozyme Therapeutics is roughly  7.52 . At this time, Halozyme Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Halozyme Therapeutics' earnings, one of the primary drivers of an investment's value.

Halozyme Therapeutics Systematic Risk

Today, most investors in Halozyme Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Halozyme Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Halozyme Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Halozyme Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Halozyme Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Halozyme Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Halozyme Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Halozyme Therapeutics's daily price indicators and compare them against related drivers.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.